Large prospective study of ovarian cancer screening in high-risk women: CA125 cut-point defined by menopausal status

Cancer Prevention Research

Volumn 4, Issue 9, 2011, Pages 1401-1408

  Skates, Steven J ^a   Mai, Phuong ^b   Horick, Nora K ^a   Piedmonte, Marion ^d   Drescher, Charles W ^e   Isaacs, Claudine ^f   Armstrong, Deborah K ^g   Buys, Saundra S ^h   Rodriguez, Gustavo C ⁱ   Horowitz, Ira R ^j   Berchuck, Andrew ^k   Daly, Mary B ^l   Domchek, Susan ^m   Cohn, David E ⁿ   Van Le, Linda ^o   Schorge, John O ^a   Newland, William ^p   Davidson, Susan A ^q   Barnes, Mack ^r   Brewster, Wendy ^s   Azodi, Masoud ^t   Nerenstone, Stacy ^u   Kauff, Noah D ^v   Fabian, Carol J ^w   Sluss, Patrick M ^a   Nayfield, Susan G ^b,x   Kasten, Carol H ^b,c   Finkelstein, Dianne M ^a   Greene, Mark H ^a   Lu, Karen ^y   more..

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^d ROSWELL PARK CANCER INSTITUTE   (United States)

^e SWEDISH MEDICAL CENTER   (United States)

^f GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^g JOHNS HOPKINS UNIVERSITY   (United States)

^h UNIVERSITY OF UTAH   (United States)

ⁱ NORTHSHORE UNIVERSITY HEALTHSYSTEM   (United States)

^j EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^k DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^l UNIVERSITY OF PENNSYLVANIA   (United States)

^m UNIVERSITY OF PENNSYLVANIA   (United States)

ⁿ THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^o UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^p IOWA METHODIST MEDICAL CENTER   (United States)

^q UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^r University of Alabama   (United States)

^s UNIVERSITY OF CALIFORNIA   (United States)

^t YALE UNIVERSITY   (United States)

^u HARTFORD HOSPITAL   (United States)

^v MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^w UNIVERSITY OF KANSAS CANCER CENTER   (United States)

^x UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^y UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CA 125 ANTIGEN; ORAL CONTRACEPTIVE AGENT;

ADULT; AGED; ARTICLE; CANCER SCREENING; CLINICAL FEATURE; DEMOGRAPHY; DRUG UTILIZATION; EARLY DIAGNOSIS; FALSE POSITIVE RESULT; FEMALE; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MENOPAUSE; OVARY CANCER; POSTMENOPAUSE; PREMENOPAUSE; PRIORITY JOURNAL; PROSPECTIVE STUDY; REFERENCE VALUE; RISK FACTOR; SCREENING TEST;

ADULT; AGED; CA-125 ANTIGEN; CONTRACEPTIVES, ORAL; ETHNIC GROUPS; FEMALE; HUMANS; MENOPAUSE; MIDDLE AGED; MULTIVARIATE ANALYSIS; OVARIAN NEOPLASMS; POSTMENOPAUSE; PREMENOPAUSE; PROSPECTIVE STUDIES; RISK;

EID: 80052601233     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-10-0402     Document Type: Article

References (17)

1. Jacobs I., Bast R.C. Jr. The CA 125 tumour-associated antigen: A review of the literature. Hum Reprod 1989;4:1-12. (Pubitemid 19069900)
2. Buys S.S., Partridge E., Greene M.H., Prorok P.C., Reding D., Riley T.L., et al. Ovarian cancer screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial: Findings from the initial screen of a randomized trial. Am J Obstet Gynecol 2005; 193:1630-1639 (Pubitemid 41540458)
3. Jacobs I.J., Skates S.J., MacDonald N., Menon U., Rosenthal A.N., Davies A.P., et al. Screening for ovarian cancer: A pilot randomised controlled trial. Lancet 1999;353:1207-1210 (Pubitemid 29168457)
4. Einhorn N., Sjovall K., Knapp R.C., Hall P., Scully R.E., Bast R.C. Jr, et al. Prospective evaluation of serum CA 125 levels for early detection of ovarian cancer. Obstet Gynecol 1992;80:14-18
5. Dorum A., Heimdal K., Lovslett K., Kristensen G., Hansen L.J., Sandvei R., et al. Prospectively detected cancer in familial breast/ovarian cancer screening. Acta Obstet Gynecol Scand 1999;78:906-911
6. Greene M.H., Piedmonte M., Alberts D., Gail M., Hensley M., Miner Z., et al. A prospective study of risk-reducing salpingo-oophorectomy and longitudinal CA-125 screening among women at increased genetic risk of ovarian cancer: Design and baseline characteristics: A Gynecologic Oncology Group study. Cancer Epidemiol Biomarkers Prev 2008;17:594-604. (Pubitemid 351469209)
7. Hannemann M., Fox R., James M. Ovarian cancer death reduction for women at high risk: Workload implications for gynaecology services. J Obstet Gynaecol 2006;26:42-44 (Pubitemid 43062152)
8. Hensley M.L., Robson M.E., Kauff N.D., Korytowsky B., Castiel M., Ostroff J., et al. Pre- and postmenopausal high-risk women undergoing screening for ovarian cancer: Anxiety, risk perceptions, and quality of life. Gynecol Oncol 2002;89:440-446 (Pubitemid 36687790)
9. Clinical trial to screen participants who are at high genetic risk for ovarian cancer-NCT00039559. 2001 [updated 2001; cited]; Available from: www.ClinicalTrials.gov.
10. Skates S.J., Pauler D.K., Jacobs I.J. Screening based on the risk of cancer calculation from Bayesian hierarchical change-point and mixture models of longitudinal markers. J Am Stat Assoc 2001;96:429-439
11. Nguyen H.N., Jacobson A., Patino-Paul R. New reference levels for CA125 in pre- and postmenopausal women. Primary Care Update Ob Gyns 1998;5:157.
12. Pauler D.K., Menon U., McIntosh M., Symecko H.L., Skates S.J., Jacobs I.J. Factors influencing serum CA125II levels in healthy postmenopausal women. Cancer Epidemiol Biomarkers Prev 2001;10:489-493 (Pubitemid 32701635)
13. Grover S., Quinn M.A., Weideman P., Koh H. Factors influencing serum CA 125 levels in normal women. Obstet Gynecol 1992;79:511-514
14. Kauff N.D., Satagopan J.M., Robson M.E., Scheuer L., Hensley M., Hudis C.A., et al. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 2002;346:1609-1615 (Pubitemid 34755668)
15. Domchek S.M., Friebel T.M., Singer C.F. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA 2010;304:1011-1012
16. Zhu C.S., Pinsky P.F., Cramer D.W., Ransohoff D.F., Hartge P., Pfeiffer R.M., et al. A framework for evaluating biomarkers for early detection: Validation of biomarker panels for ovarian cancer. Cancer Prev Res 2011;4:375-383
17. Cramer D.W., Bast R.C., Berg C.D., Diamandis E.P., Godwin A.K., Hartge P., et al. Ovarian cancer biomarker performance in prostate, lung, colorectal, and ovarian cancer screening trial specimens. Cancer Prev Res 2011;4:365-374